A Science and Technology Blog
But the government’s idea of vaccinating a “critical mass of people” for the purpose of breaking the virus transmission chain is riddled with problems. Unlike the mRNA vaccines from Pfizer…
According to the release, the Phase-3 trial has exceeded two months of median follow-up post vaccination as required by the U.S. FDA for the purpose of Emergency Use Authorization (EUA). While the…
Offering the vaccine right away to those in the placebo group will first require unblinding the study. Unblinding the study and offering the vaccine to the placebo group will make it almost impossible to gather further information on vaccine efficacy, thus making full licensure challenging.
The results were published online in The Lancet on November 19. The results are based on the study of 560 participants enrolled between May 30 and August 8. Of the…
The interim results of Moderna’s mRNA vaccine show that the vaccine has 94.5% efficacy in preventing COVID-19. The interim analysis, which was based on 95 cases, found that 90 participants…
Government has prioritised certain groups to receive the vaccine first. Which vulnerable groups do you think should receive the vaccine on priority? Frontline healthcare workers at every level should receive vaccines when…
With at least two months follow-up data likely to be available earliest only by November or December, the guidance essentially shuts the door on vaccine manufacturers making their vaccines available…
Never before have candidate vaccines been developed from scratch, tested on animals and completed early stages of human clinical trials all under six months. This is an acid test for…
